期刊文献+

子宫内膜癌组织COX-2和VEGF及KDR蛋白表达临床意义的探讨 被引量:2

Expressions of COX-2,VEGF and KDR protein and their clinical significance in endometrial carcinoma tissues
原文传递
导出
摘要 目的:分析子宫内膜癌组织COX-2、VEGF和KDR蛋白的表达及临床意义。方法:应用免疫组化法对112例子宫内膜癌组织COX-2、VEGF和KDR蛋白进行检测。结果:112例子宫内膜癌组织COX-2、VEGF和KDR蛋白的阳性率分别为47.32%、66.07%和52.68%,三者表达具有协同性。Ⅱ+Ⅲ+Ⅳ期子宫内膜癌组织COX-2、VEGF和KDR蛋白表达阳性率分别为68%、88%和72%,高于Ⅰ期41.38%、59.77%和47.13%,P<0.05。低分化子宫内膜癌组织COX-2和VEGF蛋白表达阳性率100%,高于中分化61.11%和69.44%以及高分化的29.69%和57.81%,P<0.05。肌层浸润>1/2子宫内膜癌组织COX-2、VEGF和KDR蛋白表达阳性率62.5%、96.88%和84.38%,高于肌层浸润≤1/2者41.25%、53.75%和40%,P<0.05。结论:COX-2、VEGF和KDR蛋白在子宫内膜癌织中的表达水平均较高且具有协同性。COX-2、VEGF及KDR是参与肿瘤发生、发展和转移的重要基因。 OBJECTIVE: To analyze the expressions of COX-2,VEGF and KDR protein in endometrial carcinoma in order to find their clinical significance.METHOD:The immunohistochemical method was used to detect the expressions of COX-2,VEGF and KDR protein.RESULTS: The expression rates were 47.32% for COX-2 detected,66.07% for VEGF detected and 52.68% for KDR detected respectively in 112 patients with endometrial carcinoma.The positive rates of COX-2,VEGF and KDR protein expressions in operative stage Ⅱ+Ⅲ+Ⅳ(68%,88% and 72%) were statistically higher than those in stage Ⅰ(41.38%,59.77% and 47.13%,P〈0.05).The positive rates of COX-2,VEGF protein expression in poorly differentiated group(100% and 100%) were statistically higher than those in moderately and well differentiated groups(61.11% and 29.69%;69.44% and 57.81%,P〈0.05).The positive rates of COX-2,VEGF and KDR protein expressions in myometrial invasion 〉1/2(62.5%,96.88% and 84.38%) were statistically higher than those in ≤1/2(41.25%,53.75%,40%,P〈0.05).CONCLUSIONS: The expressions of COX-2,VEGF and KDR protein in endometrial carcinoma are high.COX-2,VEGF and KDR are important genes in the carcinogenesis,development and metastasis of endometrial carcinoma.
出处 《中华肿瘤防治杂志》 CAS 2009年第22期1782-1785,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 子宫内膜肿瘤 前列腺素内过氧化物合酶 血管内皮生长因子类 免疫组织化学 endometrial neoplasms prostaglandin endoperoxide synthase vascular endothelial growth factor immunohistochemistry
  • 相关文献

参考文献19

二级参考文献51

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1365
  • 2舒晓燕,熊俊.尿激酶型纤溶酶原激活剂mRNA在卵巢癌组织中的表达及其意义[J].中国现代医学杂志,2004,14(20):57-58. 被引量:8
  • 3孙颖,王敏,王欣彦.环氧合酶-2在子宫内膜癌与癌前病变组织中的表达及临床意义[J].肿瘤防治杂志,2004,11(5):509-511. 被引量:7
  • 4来茂德.肿瘤分子生物学 [M].北京:人民卫生出版社,1999.215- 224. 被引量:1
  • 5Meada K,Cancer,1996年,77卷,858页 被引量:1
  • 6Comerci JT, Sloan C, Edwards RP, et al. Cyclooxygenase-2 expression in normal endometrium, endometrial hyperplasia, and carcinoma[ C]. Proceedings of the 32nd Ammual Meeting of the Society of Gynecologic Oncology, Nashville, Tennessee, March 3-7, 2000, Abstract 108. 被引量:1
  • 7Einstein MH, Cao QJ, Weiss H, et al. Expression of cyclooxygenase-2 in endometrial cancer in vivo [ C ]. Proceedings of the 32nd Ammual Meeting of the Society of Gynecologic Oncology,Nashville, Tennessee, March 3-7, 2000, Abstract 109. 被引量:1
  • 8Tong B J, Tan J, Tajeda L, et al. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-δin human endometrial adenocarcinoma [ J ]. Neoplasia, 2000,2 ( 6 ) :483 -490. 被引量:1
  • 9Fujiwaki R, Iida K, Kanasaki H, et al. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase [J]. Hum Pathol,2002,33(2):213-219. 被引量:1
  • 10Landen CN Jr, Mathur SP, Richardson MS, et al. Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies [J].Am J Obstet Gynecol, 2003,188(5):1174-1176. 被引量:1

共引文献80

同被引文献21

  • 1姜涛,王平.COX-2与子宫内膜癌的关系[J].实用癌症杂志,2005,20(5):477-479. 被引量:2
  • 2Gibson W,Green A,Bullard R S,et al.Inhibition of PAX2 expression results in alternate cell death pathways in prostate cancer cells differing in p53 status[J].Cancer Lett,2007,248(2):251-261. 被引量:1
  • 3Robson E J,He S J,Eccles M R.A Panorama of PAX genes in cancer and development[J].Nat Rev Cancer,2006,6(1):52-62. 被引量:1
  • 4Wu H,Chen Y,Liang J,et al.Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis[J].Nature,2005,438(7070):981-987. 被引量:1
  • 5Matzke M A,Birchler J A.RNAi-mediated pathways in the nucleus[J].Nat Rev Genet,2005,6(1):24-35. 被引量:1
  • 6Wiederschain D,Wee S,Chen L,et al.Single vector inducible lentiviral RNAi system for oncology target validation[J].Cell Cycle,2009,8(3):498-504. 被引量:1
  • 7Anthony R V,Cantlon J D.Ribonucleic acid interference:a new approach to the in vivo study of gene function[J].J Anim Sci,2007,85(13 Suppl):E18-E19. 被引量:1
  • 8Silberstein G B,Dressler G R,Van Hom K.Expression of the PAX2 oncogene in human breast cancer and its role in progesterone-dependent mammary growth[J].Oncogene,2002,21(7):1009-1016. 被引量:1
  • 9Monte N M,Webster K A,Neuberg D,et al.Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer[J].Cancer Res,2010,70(15):6225-6232. 被引量:1
  • 10Gokden N,Kemp S A,Gokden M.The utility of PAX2 as an immunohistochemical marker for renal cell carcinoma in cytopathology[J].Diagn Cytopathol,2008,36(7):473-477. 被引量:1

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部